Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring

StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Emory University
377 trials monitored
See 20 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Chronic Kidney Disease
1,423 trials monitored
See 70 trials at risk
This study will evaluate whether Continuous Glucose Monitoring (CGM) can identify previously unrecognized diabetes and clinically significant hyperglycemia in adults with end-stage kidney disease (ESKD) receiving hemodialysis who have no known history of diabetes. Participants will wear a Libre 3 Plus CGM sensor for up to 15 days and undergo standard diabetes assessments, including fasting plasma glucose and hemoglobin. The primary objectives are to: * Determine the prevalence of previously undiagnosed diabetes among dialysis patients using OGTT criteria. * Compare CGM glucose patterns between participants with and without diabetes as determined by OGTT results.
Trial Details
NCT Number NCT07880795
Lead Sponsor Emory University
Conditions
(from sponsor)		 End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
Related terms Diabetes Mellitus, Hyperglycemia, Kidney Failure, Chronic
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov